MediWound receives pediatric indication for burn treatment NexoBrid
…
18,100$
-0,11%
Echtzeit-Aktienkurs MediWound Ltd
Bid:
Ask:
Nachrichten zur MediWound Ltd Aktie
MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
…
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -61.90% and 0.18%, respectively, for the quarter ended June 2024. Do the…
Mölnlycke[®] Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
Gothenburg, Sweden. 15 July 2024. Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical…
MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
…
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 2.50% and 6.82%, respectively, for the quarter ended March 2024. Do the…
MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript
…
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 17.39% and 0.21%, respectively, for the quarter ended December 2023. Do the…
MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript
…
MediWound Q3 2023 Earnings Preview
…
MDXG: Xenografts and Synthetics Options for Expansion
By John Vandermosten, CFA
NASDAQ:MDXG
READ THE FULL MDXG RESEARCH REPORT
Third Quarter 2023 Summary
MiMedx Group, Inc. (NASDAQ:MDXG) reported third quarter 2023 revenues…
MediWound Deploys NexoBrid® for Emergency Supply
YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on…
MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 124.39% and 14%, respectively, for the quarter ended June 2023. Do the…
MediWound GAAP EPS of $0.10 beats by $0.47, revenue of $4.77M beats by $0.59M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg…
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers MediWound…
Form 6-K MediWound Ltd. For: Aug 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K MediWound Ltd. For: Aug 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Announces Commercial Launch of NexoBrid® in Japan
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and…
Form 6-K MediWound Ltd. For: Jul 17
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K MediWound Ltd. For: Jul 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 shown to be safe and well-tolerated...…
MediWound gains positive advice from EMA on phase 3 trial for EscharEx
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
Affirms the clear path forward for the Companys global Phase III study of EscharEx in venous leg ulcers Affirms the…
Form 6-K MediWound Ltd. For: Jul 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on…
Form 6-K MediWound Ltd. For: May 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound slips after Q1 miss
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -41.94% and 28.66%, respectively, for the quarter ended March 2023. Do the…
MediWound GAAP EPS of -$0.44 misses by $0.26, revenue of $3.8M misses by $1.35M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K MediWound Ltd. For: May 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash…
MediWound Q1 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for…
MediWound Announces an Additional $10 Million Award from BARDA
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension Funding to support emergency stockpiling…
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
Data to be highlighted in oral and poster presentations...…
5 Analysts Have This to Say About MediWound
Latest Ratings for MDWD
DateFirmActionFromTo Aug 2021Aegis CapitalMaintainsBuy Aug 2021HC Wainwright & Co.MaintainsBuy Mar 2021Aegis CapitalInitiates Coverage OnBuy
…
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the…
MediWound names industry veteran as CFO
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing…
Form 6-K MediWound Ltd. For: Mar 16
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for…
Form 6-K MediWound Ltd. For: Feb 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on…
Form 6-K MediWound Ltd. For: Feb 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Israeli tissue repair co MediWound raises $27.5m on Nasdaq
The company says it plans to use the net proceeds from the offering primarily for the acceleration of the development…
Form 6-K MediWound Ltd. For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
FDA approves MediWound burns treatment
Pineapple plant-based NexoBrid, is one of the first botanical drugs to receive approval in the US. It is already approved…
MediWound, Vericel gain on FDA approval of burn therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…